Clinical Trials
213 trialsContinuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event
National Institutes of Health Clinical Center (CC)
Collection of Tissue Samples for Cancer Research
National Institutes of Health Clinical Center (CC)
POM MM 014
Celgene
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
AbbVie
FOCUS
Ohio State University Comprehensive Cancer Center
TAPUR
American Society of Clinical Oncology
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie
LONGEVITI
University of Alberta
Agriculture Health Study
National Institutes of Health Clinical Center (CC)
inMMyCAR
Kelonia Therapeutics, Inc.
CER
Cancer Support Community, Research and Training Institute, Philadelphia
IFM2014-04
University Hospital, Lille
SURGE
Colorado State University
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
Washington University School of Medicine
CLOVER-WaM
Cellectar Biosciences, Inc.
EHCancer
Zagazig University
Discontinuation Study
University College Cork
DETERMINE
Cancer Research UK
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
AbbVie
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
SELECT-CAR-NK
Essen Biotech
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
AbbVie
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
Pfizer
Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells
UNC Lineberger Comprehensive Cancer Center
EREVA
Centre Hospitalier Régional d'Orléans
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
AbbVie
Plan Development for Giving Teclistamab in the Outpatient Setting
University Health Network, Toronto
POSBIO-CRC
AC Camargo Cancer Center
Effects of a Resistance Physical Exercise Program in Multiple Myeloma Patients
University of Salamanca
LIBERATE
University Health Network, Toronto
DETERMINE
Cancer Research UK
e-Motion : Promoting Emotion Regulation in Chronic Cancer
Université Libre de Bruxelles
VRd MM Fibrate
Tanta University
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
UNC Lineberger Comprehensive Cancer Center
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
University of California, San Diego
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Amgen
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)
Monash University
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)
Monash University
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)
Monash University
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)
Monash University
MITOX
IRCCS San Raffaele
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
AVR-CHEMO
Arab American University (Palestine)
ARQ 531-101
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
Barbara Ann Karmanos Cancer Institute
CARLOTTA01
Technische Universität Dresden
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
AbbVie
A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan
AbbVie